SCX as a biomarker will probably be more useful if applied together with other noninvasive IPF and SSc markers in a diagnostic-prognostic panel including chemokines (CCL18 and CXCL13), interleukins (Il-6, Il-13, and Il-8), and metalloproteinases (MMP7, MMP8, MMP9, MMP10, and MMP28) [7,55,56,57], once validated as fibrosis markers. The gene discussed is CXCL13; the disease is systemic sclerosis.